NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free LYEL Stock Alerts $2.23 +0.19 (+9.31%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.02▼$2.2650-Day Range$1.71▼$3.0752-Week Range$1.32▼$3.97Volume1.18 million shsAverage Volume863,869 shsMarket Capitalization$566.64 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lyell Immunopharma alerts: Email Address Lyell Immunopharma MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside146.6% Upside$5.50 Price TargetShort InterestBearish8.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.91) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.63 out of 5 starsMedical Sector451st out of 939 stocksPharmaceutical Preparations Industry218th out of 441 stocks 3.3 Analyst's Opinion Consensus RatingLyell Immunopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Lyell Immunopharma has a forecasted upside of 146.6% from its current price of $2.23.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.91% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 5.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYEL. Previous Next 3.2 News and Social Media Coverage News SentimentLyell Immunopharma has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lyell Immunopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LYEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders24.00% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($0.91) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Lyell Immunopharma Stock (NASDAQ:LYEL)Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More LYEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYEL Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comContrasting Universe Pharmaceuticals (NYSE:UPC) and Lyell Immunopharma (NASDAQ:LYEL)March 20, 2024 | finance.yahoo.com2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 17, 2024 | finance.yahoo.comLyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returnsMarch 10, 2024 | finanznachrichten.deLyell Immunopharma, Inc: Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingMarch 5, 2024 | globenewswire.comLyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingFebruary 28, 2024 | finance.yahoo.comLyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business HighlightsFebruary 28, 2024 | globenewswire.comLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023March 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.February 26, 2024 | globenewswire.comLyell Immunopharma Announces Participation in March Investor ConferencesFebruary 20, 2024 | investing.comLyell Immunopharma Inc (LYEL)January 30, 2024 | benzinga.comLyell Immunopharma Stock (NASDAQ:LYEL) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comLyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceDecember 19, 2023 | health.usnews.comHeather D. LyellDecember 19, 2023 | finance.yahoo.comCompanies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In GrowthNovember 10, 2023 | seekingalpha.comLyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TILNovember 10, 2023 | markets.businessinsider.comWhy Lyell Immunopharma Shares Are Rising TodayNovember 9, 2023 | msn.comLyell gets FDA orphan drug designation for melanoma drug candidateNovember 9, 2023 | finance.yahoo.comLyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of MelanomaNovember 8, 2023 | msn.comLyell Immunopharma reports Q3 resultsNovember 7, 2023 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023October 31, 2023 | finance.yahoo.comLyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL ManufacturingOctober 9, 2023 | finance.yahoo.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 49% stakeSeptember 27, 2023 | finance.yahoo.comLyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 11, 2023 | marketwatch.comLyell Immunopharma Shares Up 8% on Cellares CollaborationSeptember 11, 2023 | finance.yahoo.comCellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle PlatformAugust 31, 2023 | finance.yahoo.comLyell Immunopharma to Participate in Upcoming Investor ConferencesSee More Headlines Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees224Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$6.00 Low Stock Price Target$5.00 Potential Upside/Downside+146.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-234,630,000.00 Net Margins-180,486.14% Pretax Margin-180,486.17% Return on Equity-32.67% Return on Assets-28.78% Debt Debt-to-Equity RatioN/A Current Ratio16.07 Quick Ratio16.07 Sales & Book Value Annual Sales$130,000.00 Price / Sales4,358.79 Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.86Miscellaneous Outstanding Shares254,100,000Free Float193,113,000Market Cap$566.64 million OptionableOptionable Beta-0.50 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Richard D. Klausner M.D. (Age 72)Founder & Executive Chairman Comp: $80kDr. Lynn Seely M.D. (Age 65)Ph.D., President, CEO & Director Comp: $430.69kMr. Charles W. Newton (Age 52)Chief Financial Officer Comp: $1.72MMr. Stephen J. Hill (Age 54)Chief Operating Officer Comp: $1.04MDr. Gary Lee Ph.D. (Age 47)Chief Scientific Officer Comp: $639.91kMs. Elizabeth Homans (Age 58)Consultant Comp: $1.99MProf. Stanley R. Riddell M.D.Founder & Scientific AdvisorDr. Crystal L. Mackall M.D. (Age 63)Founder & Scientific Advisor Nellie DilleryDirector of AccountingMs. Ellen RoseSenior Vice President of Communications & Investor RelationsMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCNkartaNASDAQ:NKTXEsperion TherapeuticsNASDAQ:ESPRLexicon PharmaceuticalsNASDAQ:LXRXAlto NeuroscienceNYSE:ANROView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 3,305,693 shares on 3/11/2024Ownership: 5.354%Goldman Sachs Group Inc.Bought 90,078 shares on 3/1/2024Ownership: 0.249%Virtu Financial LLCBought 15,182 shares on 2/26/2024Ownership: 0.006%Price T Rowe Associates Inc. MDSold 47,314 shares on 2/16/2024Ownership: 2.636%Citadel Advisors LLCSold 800 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions LYEL Stock Analysis - Frequently Asked Questions Should I buy or sell Lyell Immunopharma stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LYEL shares. View LYEL analyst ratings or view top-rated stocks. What is Lyell Immunopharma's stock price target for 2024? 2 analysts have issued twelve-month price objectives for Lyell Immunopharma's shares. Their LYEL share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 146.6% from the stock's current price. View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts. How have LYEL shares performed in 2024? Lyell Immunopharma's stock was trading at $1.94 at the beginning of the year. Since then, LYEL stock has increased by 14.9% and is now trading at $2.23. View the best growth stocks for 2024 here. When is Lyell Immunopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our LYEL earnings forecast. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative trailing twelve-month return on equity of 32.67% and a negative net margin of 180,486.14%. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Lyell Immunopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.40%), Vanguard Group Inc. (5.35%), WuXi AppTec Co. Ltd. (3.25%), Price T Rowe Associates Inc. MD (2.64%), Price T Rowe Associates Inc. MD (2.64%) and Northern Trust Corp (0.59%). Insiders that own company stock include Cathy Friedman and Richard Klausner. View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LYEL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.